MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
Κύριοι συγγραφείς: | Takahashi, O, Komaki, R, Smith, P, Ryan, A, Jurgensmeier, J, Welsh, J, Jacoby, J, Hosho, K, Korshunova, M, Erez, B, Herbst, R, O'Reilly, MS |
---|---|
Μορφή: | Journal article |
Έκδοση: |
2009
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
ανά: Gupta, A, κ.ά.
Έκδοση: (2013) -
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
ανά: Dummer, R, κ.ά.
Έκδοση: (2008) -
Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
ανά: Jin-Hang Gao, κ.ά.
Έκδοση: (2022-03-01) -
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
ανά: Takahashi, O, κ.ά.
Έκδοση: (2012) -
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
ανά: Takahashi, O, κ.ά.
Έκδοση: (2012)